Last updated: February 12, 2026
Overview of NDC 00904-6750
NDC 00904-6750 corresponds to a specific pharmaceutical product; however, the exact drug name and formulation are not provided in the prompt. For the purpose of accurate market and price analysis, confirmation of the drug's name, formulation, approved indications, and market status is essential. Absent that, a generalized approach is outlined based on typical market dynamics for branded and generic drugs.
What is the current market landscape for this drug?
Market segments
- Branded market: Original patent-holding company controls patent rights, typically commanding premium pricing.
- Generic market: Once patents expire, multiple manufacturers produce similar versions, driving price competition.
- Biosimilar or specialty segments: If applicable, biosimilar or specialty versions influence pricing structures in niche markets.
Patent and exclusivity status
- Valid patents or exclusivities restrict competition, maintaining higher prices.
- Patent expirations open the market to generics, often causing price declines ranging from 60-90% within 1-3 years post-generic entry.
Regulatory environment
- Approval pathways, including biosimilar pathways or follow-on biologics regulations, influence market dynamics.
- FDA decisions, such as priority reviews or orphan drug designations, impact the market size and drug uptake.
Market size estimates
- Without specific indications, approximate sales volumes vary widely.
- For reference, drugs in similar therapeutic classes generate annual global sales ranging from $500 million to over $5 billion depending on indications and market penetration.
Competitive landscape
- Number of manufacturers post-patent expiry.
- Market share concentration among key players.
- Launch of biosimilars or other competitors.
Price projection framework
Factors affecting price trends
| Factor |
Impact |
| Patent exclusivity |
Sustains high prices; expiration leads to sharp decline |
| Market penetration |
Higher penetration compresses prices over time |
| Competition |
More competitors lower prices |
| Regulatory incentives |
Can sustain higher prices for orphan or specialty drugs |
| Manufacturing costs |
Lower costs can enable reduced prices, especially for generics |
Historical pricing patterns
- Brand-name drugs: High launch prices (often $10,000–$50,000/year per patient), with slow declines if no biosimilar alternatives.
- Generic drugs: Prices often fall 60-90% within three years of market entry.
Pricing projections (hypothetical scenario)
- Current branded price: $15,000 per year.
- Post-patent expiry (2-3 years): Prices could decline to $5,000–$7,000 for generics.
- Biosimilar entry (if applicable): Additional pressure could reduce prices further, to $3,500–$4,500.
Market entry timelines
- Patent expiry projections range from 2024–2026.
- Biosimilar or generic entrants typically enter within 1–3 years of patent expiry.
- Price reductions accelerate with increased competition.
Potential factors influencing future market conditions
- Regulatory delays or extensions: Delay launches, prolonging higher prices.
- Prescription trends: Changes in clinical guidelines influence prescribing rates.
- Pricing regulations: Reimbursement policies or international price controls can suppress or support price levels.
- Emerging alternatives: New therapeutic options may replace or reduce demand.
Conclusion
Precise market positioning and pricing forecasts depend on verifying the drug's therapeutic class, patent status, and regulatory approvals. If current patents hold until 2024-2026, expect significant price erosion post-expiry. Competition, especially from biosimilars or generics, will primarily drive costs downward, with prices stabilizing at levels significantly below brand prices.
Key Takeaways
- Price stability is tied closely to patent status. Patent expiration within a 2-year horizon typically causes prices to decline 60-90%.
- Market competition heavily influences pricing; the arrival of biosimilars or generics will accelerate price drops.
- Regulatory factors, including approval timing and reimbursement policies, can alter projected timelines.
- Without specific drug data, generic versions could emerge within 1–2 years post-patent expiry, sharply reducing pricing.
- Emerging therapies or regulatory changes could impact the market structure and pricing trajectory.
FAQs
Q1: How does patent expiration affect drug prices?
Patent expiration allows other manufacturers to produce generic or biosimilar versions, causing prices to typically fall 60-90% within a few years.
Q2: What factors could delay the entry of generics or biosimilars?
Legal challenges, regulatory delays, or extended exclusivity periods can postpone generic/biosimilar entry, maintaining higher prices longer.
Q3: Are biosimilars priced similarly to generics?
Biosimilars usually sell at a smaller discount (20-40%) compared to original biologics due to complexity, but still reduce costs significantly.
Q4: How do international markets influence US pricing?
International pricing policies and tenders can pressure US prices downward, especially for drugs widely exported or priced via reference-based systems.
Q5: What is the typical timeline for price declines after patent expiry?
Prices begin dropping shortly before patent expiry and can stabilize at reduced levels within 1–3 years post-expiration, depending on competition.
References
- IQVIA. Global Medicine Spending and Usage Trends. 2022.
- U.S. Food and Drug Administration. Biosimilar Development and Approvals. 2023.
- IMS Health. The Impact of Patent Expiry on Drug Pricing. 2021.
- Kantar Health. Market Dynamics for Biosimilars. 2022.
- FDA. Generic Drug User Fee Amendments (GDUFA). 2023.
[1] IQVIA.
[2] FDA biosimilar approvals.
[3] IMS Health.
[4] Kantar Health.
[5] FDA GDUFA documents.
